ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study of Radiolabeled ALXN2050 in Healthy Adult Males
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-ALXN2050
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04609670
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
Copper Balance in Healthy Participants Administered ALXN1840
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04594252
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04573309
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Phase 2
Active, not recruiting
- Conditions
- Lupus NephritisImmunoglobulin A Nephropathy
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04564339
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04560816
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
Phase 3
Active, not recruiting
- Conditions
- Thrombotic Microangiopathy
- Interventions
- Other: Best Supportive Care
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04557735
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04551586
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
A Study of the Effects of Food and Age on Danicopan
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04551599
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
Phase 3
Active, not recruiting
- Conditions
- Thrombotic Microangiopathy
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT04543591
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04526210
- Locations
- 🇺🇸
Clinical Trial Site, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath